复星医药(02196)将于8月25日召开董事会审议2026年中期业绩

公告速递
Aug 13

复星医药(02196)8月13日公告,公司董事会已排期于2026年8月25日(星期二)召开会议,届时将审议并通过公司及其附属公司截至2026年6月30日止六个月的中期业绩,并于会后予以刊发。

公告显示,董事会主席陈玉卿以董事会名义发布该通知。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10